{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["31(8)"],"submitter":["Yoo DS"],"pubmed_abstract":["<h4>Background and purpose</h4>IV administration of tPA is accepted as a standard treatment for acute cerebral ischemia, but the clinical outcomes cannot be guaranteed in patients who are not recanalized after IV-tPA and in those who are not eligible for IV-tPA. In this study, outcomes from groups of patients treated with additional IA thrombolytic therapy with the use or omission of IV-tPA administration were compared.<h4>Materials and methods</h4>IA thrombolytic therapy (thrombolytic agents combined with mechanical intervention) was attempted in those patients who were not eligible for IV-tPA and who showed continuous major vessel occlusion after IV-tPA. Sixty-three patients were divided into 2 groups: a tPA group (n = 29, IA thrombolysis after IV-tPA) and a non-tPA group (n = 34, IA thrombolysis without IV-tPA). These groups were subdivided according to match or mismatch DWI/PWI after MR imaging. Treatment results were compared by recanalization rate, clinical outcome, mortality, and ICH rate.<h4>Results</h4>The recanalization rate was 79.3% in the tPA group and 55.9% in the non-tPA group (χ(2) test, P < .05). Subgroup analysis between DWI/PWI mismatch in the tPA group and DWI/PWI mismatch in the non-tPA group also showed no statistical difference in recanalization rate, favorable clinical outcome, and mortality (χ(2) test, P > .05), but the significant ICH rate was high in the tPA group (χ(2) test, P < .05).<h4>Conclusions</h4>Additional IA thrombolytic treatment after full-dose IV-tPA administration might be an acceptable treatment option for patients with DWI/PWI mismatch."],"journal":["AJNR. American journal of neuroradiology"],"pagination":["1536-40"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7966079"],"repository":["biostudies-literature"],"pubmed_title":["Therapeutic results of intra-arterial thrombolysis after full-dose intravenous tissue plasminogen activator administration."],"pmcid":["PMC7966079"],"pubmed_authors":["Won YD","Huh PW","Kang SG","Shin HE","Yoo DS","Lee SB","Kim KT","Cho KS"],"additional_accession":[]},"is_claimable":false,"name":"Therapeutic results of intra-arterial thrombolysis after full-dose intravenous tissue plasminogen activator administration.","description":"<h4>Background and purpose</h4>IV administration of tPA is accepted as a standard treatment for acute cerebral ischemia, but the clinical outcomes cannot be guaranteed in patients who are not recanalized after IV-tPA and in those who are not eligible for IV-tPA. In this study, outcomes from groups of patients treated with additional IA thrombolytic therapy with the use or omission of IV-tPA administration were compared.<h4>Materials and methods</h4>IA thrombolytic therapy (thrombolytic agents combined with mechanical intervention) was attempted in those patients who were not eligible for IV-tPA and who showed continuous major vessel occlusion after IV-tPA. Sixty-three patients were divided into 2 groups: a tPA group (n = 29, IA thrombolysis after IV-tPA) and a non-tPA group (n = 34, IA thrombolysis without IV-tPA). These groups were subdivided according to match or mismatch DWI/PWI after MR imaging. Treatment results were compared by recanalization rate, clinical outcome, mortality, and ICH rate.<h4>Results</h4>The recanalization rate was 79.3% in the tPA group and 55.9% in the non-tPA group (χ(2) test, P < .05). Subgroup analysis between DWI/PWI mismatch in the tPA group and DWI/PWI mismatch in the non-tPA group also showed no statistical difference in recanalization rate, favorable clinical outcome, and mortality (χ(2) test, P > .05), but the significant ICH rate was high in the tPA group (χ(2) test, P < .05).<h4>Conclusions</h4>Additional IA thrombolytic treatment after full-dose IV-tPA administration might be an acceptable treatment option for patients with DWI/PWI mismatch.","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Sep","modification":"2024-12-04T07:41:46.843Z","creation":"2022-02-09T10:49:19.72Z"},"accession":"S-EPMC7966079","cross_references":{"pubmed":["20395391"],"doi":["10.3174/ajnr.a2084","10.3174/ajnr.A2084"]}}